etiocholanolone has been researched along with Ventricular Dysfunction, Left in 2 studies
Etiocholanolone: The 5-beta-reduced isomer of ANDROSTERONE. Etiocholanolone is a major metabolite of TESTOSTERONE and ANDROSTENEDIONE in many mammalian species including humans. It is excreted in the URINE.
3alpha-hydroxy-5beta-androstan-17-one : An androstanoid that is 5beta-androstane substituted by an alpha-hydroxy group at position 3 and an oxo group at position 17. It is a metabolite of testosterone in mammals.
Ventricular Dysfunction, Left: A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate: 1) the effects of dobutamine (DOB) on left ventricular function in early (48-72 h) and late (14 days) phases of a post-MI canine model, compared to ISTA, and 2) the efficacy of DOB in chronic left ventricular dysfunction (6 months post-MI) in dogs pre-treated or not with a beta-blocker, compared with ISTA and milrinone (MIL)." | 3.74 | Sympathomimetic inefficiency in restoring contractility in the acute or chronic beta-blocker-treated ischaemic heart: comparison with a new agent. ( Borsini, F; Carminati, P; Gagnol, JP; Loi, FM; Mattera, GG; Vanoli, E, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mattera, GG | 2 |
| Vanoli, E | 2 |
| Gagnol, JP | 2 |
| Loi, FM | 1 |
| Borsini, F | 1 |
| Carminati, P | 2 |
| Adamson, PB | 1 |
| Germany, R | 1 |
| Schwartz, PJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study to Assess the Hemodynamic Effects of Istaroxime, a Novel Lusinotropic Agent, in Patients Hospitalized With Worsening Heart Failure and a Reduced Left Ventricular Systolic Function[NCT00616161] | Phase 2 | 120 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for etiocholanolone and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Sympathomimetic inefficiency in restoring contractility in the acute or chronic beta-blocker-treated ischaemic heart: comparison with a new agent.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Cardiotonic Agents; Dobutamine; Dogs | 2008 |
Hemodynamic effects of a new inotropic compound, PST-2744, in dogs with chronic ischemic heart failure.
Topics: Animals; Cardiotonic Agents; Dobutamine; Dogs; Etiocholanolone; Heart Failure; Hemodynamics; Ventric | 2003 |